Press Room > April 2008 Archives

« February 2008 | Main | July 2008 »

Bioponic Phytoceuticals Appoints Renowned Physician Dr. Barbara Nabrit-Stephens to Scientific Advisory Board

KULA, MAUI, Hawaii, April 22 /PRNewswire-FirstCall/ --BPI logo

Bioponic Phytoceuticals, Inc. (OTC Bulletin Board: BPYT - News; "Bioponic" or "the Company") today announced that Dr. Barbara Anne Nabrit-Stephens, MD, MBA, FAAP has joined the Company's Scientific Advisory Board. Dr. Nabrit-Stephens is a board-certified pediatrician with over 30 years of health care experience. As a scientific advisor, Dr. Nabrit-Stephens will help validate and formulate Bioponic's strategies to market its all-natural therapeutic products, including Curecumin(TM) and Curmisinin(TM).

"We are honored to welcome Dr. Nabrit-Stephens to our Scientific Advisory Board. Dr. Nabrit-Stephens' in-depth experience as both a clinician and health care administrator is a true asset to our organization," said Steven M. Schorr, Chairman and CEO of Bioponic. "Testing and research programs for Alzheimer's applications for Curecumin(TM) and distribution of Curmisinin(TM) to treat the deadly cerebra malaria, which kills over 2 million children in Sub-Saharan Africa, are the first projects Dr. Nabrit-Stephens will be involved in. She is also ideally suited to advise us on our newest product line, Gentle Mother, specifically for the needs of newborns and infants."

Dr. Nabrit-Stephens said, "I've always been attracted to those companies who focus on providing pro-active healthcare solutions, especially to those populations at-risk. Bioponic's work in bringing all-natural treatments to control devastating malaria in Africa is very impressive. I believe Bioponic's Bioresonant formulations could potentially represent a breakthrough in the treatment of epidemic disease. I am intrigued to discover more about the Company and their product lines, and look forward to our ongoing collaboration."

Continue reading "Bioponic Phytoceuticals Appoints Renowned Physician Dr. Barbara Nabrit-Stephens to Scientific Advisory Board" »

Bioponic Phytoceuticals Announces Curecumin(TM) May Lower Heart Failure Risk

KULA, Maui, April 16 /PRNewswire/ -- Bioponic Phytoceuticals, Inc. (OTC: BPYT - News; "Bioponic" or "theCurecumin Company") today announced that curcumin, the key ingredient in the Company's Curecumin(TM) product (a Bioresonant Phytotherapeutic® form of curcumin in a liquid delivery system) may be an important treatment for lowering heart failure risk. Bioponic currently sells Curecumin in a 1 oz. oral spray and a 1 oz. nasal pump spray bottle. Research findings and product information on Curecumin's many therapeutic qualities can be found at http://www.curecumin.com.

In a recent study entitled, "Curcumin prevents and reverses murine cardiac hypertrophy," published in the February 2008 edition of the Journal of Clinical Investigation, researchers found that when the herb was given orally to a variety of mouse models with enlarged hearts (hypertrophy), it can prevent and reverse hypertrophy, restore heart function and reduce scar formation.

"Whether you are young or old; male or female; the larger your heart is, the higher your risk is for developing heart attacks or heart failure in the future," explains Dr. Liu, a cardiologist in the Peter Munk Cardiac Centre at the Canadian Institutes of Health Research - Institute of Circulatory and Respiratory Health. If clinical trials of curcumin support initial findings of heart enlargement prevention, it may offer hope for millions of patients with heart enlargement. Dr. Liu, who holds the Heart and Stroke Foundation's Polo Chair Professor in Medicine and Physiology at the University of Toronto, says that curcumin may be a safe and effective means of preventing heart failure in the future. This study was funded by the Heart and Stroke Foundation and the Canadian Institutes of Health Research.

"Curcumin has been the subject of extensive research over the past few years, and has been shown to protect the liver, inhibit tumors, reduce inflammation and prevent the formation of the amyloid beta plaques which cause Alzheimer's Disease. We are encouraged by yet another study that suggests the versatile curcumin may lower heart failure risk," said Steven M. Schorr, Chairman and CEO of Bioponic. "More than 5 million Americans are living with heart failure, and 550,000 new cases are diagnosed each year, according to the American Heart Association. The potential that our Curecumin(TM) product (http://www.curecumin.com) could provide a viable treatment strategy for those at risk for heart failure is very exciting. If proven effective, we may have an efficacious, cost effective, natural treatment for heart failure sufferers."

Bioponic Phytoceuticals Announces Master Distributorship with Nature's Best Covering 1,000 West Coast Retailers

MAUI, Hawaii: April 14, 2008:

Bioponic Phytoceuticals, Inc. ("Bioponic" or "the Company") (OTC: BPYT)Phyto Logo

announced today that Nature's Best, the largest privately-owned wholesaler-distributor of health and natural food products in the Natural Products industry, has been named the Company's Master Distributor covering the Western United States. Effective April 1, 2008, Nature's Best is responsible for distributing five of Bioponic's most popular consumer brands to approximately 1,000 health food stores and natural product retailers in the Western United States.

Bioponic's all natural, organic health and wellness products scheduled for distribution are: Hawaiian Healing Mist™, O-Spray™, Throat Note™, Gentle Mother™ and Noni Healing Tonic, representing a total of 11 products. Individual product descriptions may be found by visiting Bioponic's website at http://www.bioponic.com.

“We are thrilled to be represented by Nature's Best. Their well-earned reputation of bringing the finest in certified organic, natural and specialty products to retail markets is a boon for our company. This master distributorship is a unique opportunity to build upon the local and online retail success of our core skin care and wellness product lines, as well as promote our latest all-natural lines like Gentle Mother,” said Steven M. Schorr, Chairman & CEO of Bioponic.

Schorr concluded, “We anticipate solid representation across retail shelves in the Western United States, including key markets with highly favorable demographics in the state of California, will help us ramp up product revenues throughout 2008.”  

Continue reading " Bioponic Phytoceuticals Announces Master Distributorship with Nature's Best Covering 1,000 West Coast Retailers" »

Curecumin May Be Potential Treatment For Lung Cancer

 HULIQ logo

HULIQ.com Public News Organization Posted in: Health Lung Cancer Lung Cancer Treatment

Bioponic Phytoceuticals has announced that its Curecumin (a Bioresonant Phytotherapeutic form of Turmeric containing curcumin in a liquid nasal delivery system) may be an important treatment for Lung Cancer.

In a recent study published in Science Direct, “Induction of Apoptosis in Human Lung Cancer Cells by Curcumin,” conducted at the Department of Medicine, Pediatrics and Family and Preventive Medicine, School of Medicine, University of California, San Diego, scientists concluded, “Curcumin, a phenolic compound from the rhizome of the plant Curcuma longa has anti-inflammatory, antioxidant and anti-cancer activities…

This study investigated the cellular and molecular changes induced by curcumin leading to the induction of apoptosis in human lung cancer cell lines — A549 and H1299… Curcumin inhibited the growth of both the cell lines in a concentration dependent manner… Curcumin induced apoptosis in both the lung cancer cell lines.”

“We are particularly interested in the potential of our Curecumin(TM) product to provide a viable treatment strategy for those with lung cancer. Especially, because the liquid form of Curecumin, in a nasal delivery system, will send the formula directly to the lungs. If proven effective, we may have an efficacious, cost effective, natural treatment for lung cancer sufferers.” said Steven M. Schorr, Chairman & CEO — Bioponic Phytoceuticals, Inc.